Hunter Syndrome Treatment Market Competitive Landscape, Opportunity and Market Growth Challenges 2019-2025

[Jan, 2019] The global hunter syndrome treatment market size is estimated to reach a value of USD 1.4 billion by 2025, registering a CAGR of 7.6% during the forecast period. Rising patient population living with Hunter syndrome, increasing healthcare expenses, and potential approval of pipeline drugs worldwide are some of the major factors fueling market growth.

Hunter syndrome, which is also known as mucopolysaccharidosis type II (MPS II), is caused by iduronate-2-sulfatase enzyme deficiency. The treatment mainly focuses on management of symptoms, indications, and disease progression-associated complications, since there is no permanent cure for Hunter syndrome. Existing treatment includes enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT). Disease diagnosis is usually determined by a blood test for iduronate-2-sulfatase deficiency and occurs early in life based on the appearance of skeletal abnormalities.

Request A Sample Copy of this Market Report @:
https://www.radiantinsights.com/research/hunter-syndrome-treatment-market/request-sample

Enzyme replacement therapy held the largest share among current treatment options in the market. This can be attributed to strong revenue generated by Shire's ELAPRASE, an ERT prescribed worldwide to improve walking capacity and reduce spleen volume in patients of 5 years of age and older.

North America led the Hunter syndrome treatment market in 2017 with a share of close to 40.0%. This can be attributed to developed healthcare facilities in the region and increased investment in R&D of novel therapies. While novel treatments including ERTs and HSCTs are gaining penetration in developed markets, high cost of therapy poses as a hurdle in developing regions.

Further key findings from the study suggest:

• Hunter syndrome affects around one per 160,000 males. It is an X-linked recessive disorder and women are far less at a risk of developing this disease

• The enzyme replacement therapy segment acquired the largest share in 2017 and is expected to hold its leading position through the forecast period due to increased adoption of ELAPRASE and potential approval of Hunterase worldwide

• North America dominated the Hunter syndrome treatment market in 2017 due to well-established healthcare infrastructure and favorable reimbursement policies

• The APAC region is expected to witness the fastest growth due to rising disease cohort driven by increasing healthcare expenses

• Some of the key players in the market are Shire Plc.; GC Pharma; JCR Pharmaceuticals Co Ltd.; RegenxBio Inc.; Sangamo Therapeutics; ArmaGen Inc.; Inventiva; Denali Therapeutics Inc.; Esteve; and Bioasis Technologies Inc.

Browse Full Research Report of this Market With TOC @:
https://www.radiantinsights.com/research/hunter-syndrome-treatment-market

Table of Contents:

Chapter 1 Methodology and Scope
1.1 Research Methodology
1.1.1 Information procurement
1.2 Information or Data Analysis
1.3 Market Formulation & Validation
1.4 Region-wise Market Calculation
1.4.1 Region-Wise Market: Base Estimates
1.4.2 Global Market: CAGR Calculation
1.5 Region-based Segment Share Calculation
1.6 List of Secondary Sources
1.7 List of Primary Sources
1.7.1 Primary interview breakup
1.7.1.1 Data for primary interviews, by sources
1.7.1.2 Data for primary interviews, by region

Chapter 2 Executive Summary
2.1 Market Snapshot

Chapter 3 Hunter Syndrome Treatment Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.2 Market Driver Analysis
3.3 Market Restraint Analysis
3.4 Key Opportunities Prioritized
Continued...

Explore Other Reports of this category By Radiant Insights,Inc at:
https://www.radiantinsights.com/catalog/pharmaceutical

Contact Details:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
28 2nd Street, Suite 3036, San Francisco, CA 94105, United States
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com